Jan 10, 2023 / 11:45PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
Great. Good afternoon, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we are delighted to be continuing the conference with Halozyme. We're going to stay in this room for Q&A after the presentation. So there's 2 ways to ask a question. (Operator Instructions)
So with that out of the way, let me turn it over to Halozyme's CEO, Dr. Helen Torley.
Helen I. Torley - Halozyme Therapeutics, Inc. - President, CEO & Director
Thank you, Jess. 2022 was a transformative year for Halozyme. We project we'll have grown our total revenues by more than 50% to $655 million and growing our royalty revenues by more than 70% to more than $350 million. And we also strengthened our leadership in drug delivery with the addition of our auto-injector platform. I'm pleased to share with you today how this broadened portfolio is resulting in long-term durable growth in both revenue and EBITDA.
In the course of the presentation, I will be making forward-looking
Halozyme Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers